Janux Therapeutics, Inc. Stock-Based Compensation
Janux Therapeutics, Inc. (JANX) reported Stock-Based Compensation of $9.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Janux Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $9.06M, a 17.32% decline year-over-year.
- Janux Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $9.27M, a 13.39% decline year-over-year.
- Janux Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $9.52M, a 52.22% increase year-over-year.
- Janux Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $9.04M, a 41.22% decline year-over-year.
- Janux Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $40.22M, a 21.81% increase from fiscal 2024.
- Janux Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $33.02M, a 65.06% increase from fiscal 2023.
- Janux Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $20.00M, a 16.29% increase from fiscal 2022.
- Janux Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $17.20M, a 148.96% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.06M 10-Q · filed 2026-08-06 | $18.33M 10-Q · filed 2026-08-06 | $27.85M derived: sum of 3 quarters · filed 2026-08-06 | $36.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.27M 10-Q · filed 2026-05-07 | $18.78M derived: sum of 2 quarters · filed 2026-05-07 | $27.83M derived: sum of 3 quarters · filed 2026-05-07 | $38.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.56M derived: sum of 2 quarters · filed 2026-02-26 | $29.52M derived: sum of 3 quarters · filed 2026-08-06 | $40.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | $9.04M 10-Q · filed 2025-11-06 | $20.00M derived: sum of 2 quarters · filed 2026-08-06 | $30.71M 10-Q · filed 2025-11-06 | $36.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.96M 10-Q · filed 2026-08-06 | $21.66M 10-Q · filed 2026-08-06 | $27.91M derived: sum of 3 quarters · filed 2026-08-06 | $43.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $10.70M 10-Q · filed 2026-05-07 | $16.95M derived: sum of 2 quarters · filed 2026-05-07 | $32.34M derived: sum of 3 quarters · filed 2026-05-07 | $38.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.64M derived: sum of 2 quarters · filed 2026-02-26 | $27.39M derived: sum of 3 quarters · filed 2026-02-26 | $33.02M 10-K · filed 2026-02-26 |
| 2024-09-30 | $15.39M 10-Q · filed 2025-11-06 | $21.14M derived: sum of 2 quarters · filed 2025-11-06 | $26.77M 10-Q · filed 2025-11-06 | $31.25M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $5.76M 10-Q · filed 2025-08-07 | $11.38M 10-Q · filed 2025-08-07 | $15.87M derived: sum of 3 quarters · filed 2026-02-26 | $20.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.63M 10-Q · filed 2025-05-08 | $10.11M derived: sum of 2 quarters · filed 2026-02-26 | $14.66M derived: sum of 3 quarters · filed 2026-02-26 | $20.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.03M derived: sum of 2 quarters · filed 2026-02-26 | $14.53M derived: sum of 3 quarters · filed 2026-02-26 | $20.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.55M 10-Q · filed 2024-11-06 | $10.05M derived: sum of 2 quarters · filed 2024-11-06 | $15.52M 10-Q · filed 2024-11-06 | $19.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $5.50M 10-Q · filed 2024-08-07 | $10.97M 10-Q · filed 2024-08-07 | $15.18M derived: sum of 3 quarters · filed 2025-02-27 | $19.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.47M 10-Q · filed 2024-05-08 | $9.68M derived: sum of 2 quarters · filed 2025-02-27 | $14.27M derived: sum of 3 quarters · filed 2025-02-27 | $18.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $8.80M derived: sum of 2 quarters · filed 2025-02-27 | $13.24M derived: sum of 3 quarters · filed 2025-02-27 | $17.20M 10-K · filed 2025-02-27 |
| 2022-09-30 | $4.60M 10-Q · filed 2023-11-07 | $9.04M derived: sum of 2 quarters · filed 2023-11-07 | $13.00M 10-Q · filed 2023-11-07 | $15.94M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $4.44M 10-Q · filed 2023-08-08 | $8.40M 10-Q · filed 2023-08-08 | $11.35M derived: sum of 3 quarters · filed 2023-08-08 | $13.91M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $3.96M 10-Q · filed 2023-05-09 | $6.90M derived: sum of 2 quarters · filed 2023-05-09 | $9.47M derived: sum of 3 quarters · filed 2023-05-09 | $10.74M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $5.51M derived: sum of 2 quarters · filed 2023-03-10 | $6.79M derived: sum of 3 quarters · filed 2023-03-10 | $6.91M 10-K · filed 2023-03-10 |
| 2021-09-30 | $2.57M 10-Q · filed 2022-11-10 | $3.84M derived: sum of 2 quarters · filed 2022-11-10 | $3.97M 10-Q · filed 2022-11-10 | $4.01M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.28M 10-Q · filed 2022-08-09 | $1.40M 10-Q · filed 2022-08-09 | $1.44M derived: sum of 3 quarters · filed 2022-08-09 | $1.47M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $123.00K 10-Q · filed 2022-05-10 | $163.00K derived: sum of 2 quarters · filed 2022-05-10 | $191.00K derived: sum of 3 quarters · filed 2022-05-10 | $193.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $68.00K derived: sum of 2 quarters · filed 2022-03-18 | $70.00K derived: sum of 3 quarters · filed 2022-03-18 | $72.00K 10-K · filed 2022-03-18 |
| 2020-09-30 | $28.00K 10-Q · filed 2021-11-09 | $30.00K derived: sum of 2 quarters · filed 2021-11-09 | $32.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $2.00K 10-Q · filed 2021-08-10 | $4.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |